Communiqués de presse Archive - Page 7 of 19 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Updates on Tedopi®, a Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences

OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer

OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results

OSE Immunotherapeutics Announces Participation In Upcoming Investor Conferences

OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2022

OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics Reports on its 2022 Combined General Shareholder’s Meeting

OSE Immunotherapeutics Announces Collaboration with Microsoft

OSE Immunotherapeutics Appoints its International Scientific Advisory Board

Précédent
1
…
4
5
6
7
8
9
10
…
19
Suivant